Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | DBH | P09172 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.40 |
| ▸ | HPGD | P15428 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 8/20 | 0.39 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24541019 | 0.84 | NPC1 (0.50) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL24920662 | 0.84 | NPC1 (0.50) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL24920215 | 0.82 | NPC1 (0.54) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL16639705 | 0.81 | NPC1 (0.47) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL16639727 | 0.80 | RAB9A (0.70) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL24307522 | 0.79 | NPC1 (0.55) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL30645370 | 0.79 | KMT2A (0.50) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL26264034 | 0.79 | NPC1 (0.50) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL16646581 | 0.79 | KMT2A (0.50) | NPC1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL1233875 | 0.78 | NPC1 (0.50) | NPC1RAB9AMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220118105-A1 | CD38 Antibody Drug Conjugate | SORRENTO THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | US | disclosed |
| US-11191845-B2 | CD38 antibody drug conjugate | SORRENTO THERAPEUTICS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220118105-A1 | CD38 Antibody Drug Conjugate | CD38, CD22, CD2 | NPC1 2676/4885RAB9A 1898/4885MEN1 2313/4885 |
| US-11191845-B2 | CD38 antibody drug conjugate | CD38, CD22, CD2 | NPC1 2676/4885RAB9A 1898/4885MEN1 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.